Search
MediciNova Inc
MNOVAdd to Watchlist
1.410USD
+0.010+0.71%
Close 10-27 16:00（ET）
69.65MMarket Cap
LossP/E TTM
MediciNova Inc (MNOV) Stock Price Target & Forecast
Analyst Rating
Based on 4 analysts giving stock ratings to MediciNova Inc in the past month.
Buy
0 Strong Buy
4 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
8.250USD+489.29%
MNOV Analyst Recommendation Trends
In the current month, MNOV has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MNOV average Analyst price target in the last month is 8.250.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
0
0
0
0
0
0
0
0
4
4
3
3
3
4
4
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
4
3
3
3
4
4
2
MNOV Analyst Rating for Peer Comparison
Updated: Oct 27, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
Biontech SE
BNTX
4
12
8
0
0
24
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Cytokinetics Inc
CYTK
5
16
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Financial Forecasting
Based on analysts' estimates, MNOV EPS is projected to reach -0.063 in FY2026Q3, following reported EPS of -0.047 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.10
-0.07
-0.06
-0.06
-0.08
Actual
-0.06
-0.05
-0.05
--
--
Surprise
+39.94%
+24.94%
+25.75%
--
--
FAQs
What is MediciNova Inc's expected revenue for the next quarter?
MediciNova Inc's expected revenue is 50.00K.
What is MediciNova Inc's price target?
Analysts forecast that MediciNova Inc's price target is USD 8.25, with the highest forecast at USD 11.00 and the lowest forecast at USD 6.00.
How have MediciNova IncMNOV's recent earnings per share performed?
The market expectation was USD -0.05, while MediciNova IncMNOV's earnings per share (EPS) for the previous quarter was USD -0.05. EPS for the next quarter is expected at USD -0.06.
What is the analyst rating for MediciNova Inc?
Based on the ratings of MediciNova Inc's stock from 4 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.